Frequently Asked Questions

Technologies that have been disclosed to MSIP and have been filed on, or have the potential to have, an Intellectual Property (IP) position with a likely commercial outcome and clinical impact.

Projects can be designed to advance exciting technologies that have the potential to become products, such as: medical devices, diagnostics, digital health, or therapeutics. The i3A is not a funding mechanism to support basic research or generate results for grant applications.

The i3A is not grant funding: there is no Principal Investigator (PI) salary support. Funding is released on a milestone basis as a project progresses. If a project does not pass a milestone or there are delays, funding for the next milestone will not be released automatically.

Proposals must be submitted by a PI with laboratory space at Mount Sinai, and the technology must first be disclosed to MSIP.

MSIP is in charge of protecting and commercializing Intellectual Property (IP) that results from research conducted at Mount Sinai. Projects considered for the i3A will be evaluated for commercial potential and MSIP will be involved so that any related IP is protected prior to public disclosure.

In contrast to traditional research grants, the i3 Accelerator is exclusively focused on funding the development of commercial products. The experiments required to develop products are not typically emphasized in academic labs and are often the specialty of outside organizations such as CROs. In some cases, venture capital or industry representatives are more likely to partner with Mount Sinai to further research when key experiments are repeated outside of academic labs to verify the results. Experiments that de-risk a technology and make partnership more likely are ideal projects for the i3 Accelerator.

Accelerator-funded projects will include “tranched” budgets, meaning the funding of later stages is contingent on successful completion of earlier phases and obtaining positive results. Milestones should be designed around steps that incrementally de-risk the technology and justify further investment that will continue to increase the value of the asset.

Yes, a proposal can have multiple PIs as long as they are all Mount Sinai faculty. No PI salaries will be supported by accelerator funds.

Questions? Contact us at You may also reach out to Louise Lammers, PhD, Director, Business Development, Emerging Assets at or William Chiang, PhD, Business Development Consultant, at